Clinuvel Pharmaceuticals Limited ADR (CUVL)
NASDAQ: CUVLMiscellaneousMiscellaneousUSD
At close: Oct 8, 3:57 PM ET · Delayed 15 min
CUVL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $282.73M
- P/E (TTM)
- 12.44
- EPS (TTM)
- $0.45
- Dividend yield
- 0.89% ($0.05)
- Ex-dividend date
- Sep 8, 2026
- 52-week range
- 5.53 – 8.92
- Day range
- 5.53 – 5.60
- Volume / Avg
- 11.88K / 12.84K
- Beta
- —
- Shares outstanding
- 50.49M
52-week range
CUVL stock today
Clinuvel Pharmaceuticals (CUVL) closed at $5.60 on Oct 8, down 3.45% (-$0.20), versus the S&P 500's 0.47% decline. At this level, CUVL sits near the bottom of its 52-week range of $5.53 to $8.92: 37.2% below the high, set on Dec 29, 2025 and 1.4% above the low. CUVL is down 31.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 29.7%.
Clinuvel Pharmaceuticals trades at 12.4x its trailing twelve-month earnings per share of $0.45. Clinuvel Pharmaceuticals pays an annual dividend of $0.05 per share, a 0.89% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Clinuvel Pharmaceuticals
Company profileClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
- Sector
- Miscellaneous
- Industry
- Miscellaneous
- CEO
- Dr. Philippe Jacques Wolgen M.B.A., M.D.
- Headquarters
- Melbourne, VIC
- Website
- clinuvel.com
Dividends
Dividend history- Annual dividend
- $0.05
- Dividend yield
- 0.89%
- Last payment
- $0.036
- Ex-dividend date
- Sep 8, 2026
Clinuvel Pharmaceuticals peers
Miscellaneous sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DXSTDecent Holding Inc Class A | 1.82 | -5.70% | $4.35M | vs CUVL |
| CDTGCDT Environmental Technology Investment Holdings Limited | 1.24 | +14.81% | $3.75M | vs CUVL |
| FERGFerguson Enterprises Inc. | 216.62 | +0.73% | $41.91B | vs CUVL |
Indexes, lists and sector
Appears in lists
Clinuvel Pharmaceuticals stock FAQ
What is Clinuvel Pharmaceuticals's stock price today?
CUVL last traded at $5.60 as of Oct 8, 3:57 PM EDT, down 3.45% on the day. Prices are delayed at least 15 minutes.
Does Clinuvel Pharmaceuticals pay a dividend?
Yes. Clinuvel Pharmaceuticals pays $0.05 per share annually, a 0.89% yield. The most recent dividend of $0.036 had an ex-dividend date of Sep 8, 2026.
What is CUVL's P/E ratio?
CUVL trades at a trailing P/E ratio of 12.44.
Who is Clinuvel Pharmaceuticals's CEO?
Dr. Philippe Jacques Wolgen M.B.A., M.D. is the chief executive officer of Clinuvel Pharmaceuticals Limited ADR.
What is the CUVL 52-week high?
The 52-week high for CUVL is $8.92 and the 52-week low is $5.53. The stock is currently 37.2% below its high.